Toxoplasmosis, among hematopoietic stem cell transplant (HSCT) recipients, was formerly considered as a rare disease with incidences reported varying from 0.8 to 8% depending on the seroprevalence of T. gondii in the studied population [1, 2] . However, recent data highlighted post-HSCT toxoplasmosis as a potential life-threatening disease with a poor prognosis and reported mortality rates of up to 60% [3, 4] . Additionally, it has been shown that a considerable part of post-HSCT cases are diagnosed only after death, especially in those patients with disseminated disease [3, 4] .
Post-HSCT toxoplasmosis is usually a result of a reactivation of a latent infection in seropositive patients instead of a primary infection [5] . Moreover, in this setting T. gondii may cause a severe invasive single-organ disease and the brain is the most frequently affected site, although disseminated disease has also been reported [6] . Most cases occur within the first 100 days after transplant and the highest-risk patients are seropositive allo-HSCT recipients who have received cord blood transplant, unrelated donor graft, T-cell depleted transplants, those who had high-grade graft-versus-host disease (GVHD), or are unable to take trimethoprin-sulphametoxazole (TMP/SMX) for Pneumocystis jirovecii prophylaxis (PJP) [2, 7] .
In Brazil, as in Latin America and some regions in Central Europe the seroprevalence of toxoplasmosis is considered high with rates ranging from 50 to 80% over the country [8] [9] [10] . These rates are of interest, since the majority of our HSCT patients has a positive T. gondii serology pre-transplant, which puts them at risk for toxoplasmosis reactivation after transplant. Given that, we retrospectively analyzed all cases of toxoplasmosis among those patients who underwent HSCT at the Hospital das Clínicas of São Paulo University, Brazil, between January 2010 and April 2016. Medical charts and electronic records were reviewed to retrieve demographic information, underlying malignancy, the type and date of HSCT, GVHD characteristics, T. gondii serological status, conditioning regimen, use of corticosteroids, use of trimethoprinsulphametoxazole (TMP/SMX) prophylaxis, symptoms at presentation, time from HSCT to diagnose, toxoplasmosis definition, as well as type of treatment and outcome. Toxoplasma gondii serology screening using enzyme-linked immunosorbent assay (ELISA) and immunofluorescence antibody assay (IFA) was done for all patients before transplant. Polymerase chain reaction (PCR) using primers for 529 bp repeated element (RE) sequence was performed on blood, cerebrospinal fluid, bronchoalveolar lavage, and skin, to investigate toxoplasmosis disease considering the current definition [1] .
A total of 771 patients underwent HSCT, of which 509 autologous (auto-HSCT) and 262 allogeneic (allo-HSCT), between January 2010 and April 2016. Among allo-HSCT, 216 were from a related donor, 39 from an unrelated donor and 7 from a haploidentical donor. The underlying diseases were as follows: Acute Myeloid Leukemia (AML) (4); Hodgkin's Lymphoma (1) and Acute Lymphoblastic Leukemia (ALL) (1) . Patients characteristics are shown in Table 1 . During the study period, we identified six patients who had been diagnosed with toxoplasmosis disease at our institution, representing an incidence of 0.8 and 2% among all recipients and allo-recipients, respectively. This rate is slightly higher than those previously observed in another Brazilian cohort [11] , and is even greater when compared to those reported by studies conducted in low prevalence countries such as USA [12] .
All cases occurred in seropositive T. gondii patients, which is consistent with the high seroprevalence of the disease in our country. The pre-HSCT toxoplasma seropositivity has been previously identified as the most important risk factor for toxoplasmosis reactivation [1, 2] and our finding corroborates the importance of determining the toxoplasma serology status before transplant, especially in patients from high endemicity areas. Additionally, it also suggests that the reactivation of a latent cyst was probably the mechanism implicated in our cases.
Of the six cases of toxoplasmosis, five were defined as probable and 1 as proven toxoplasmosis. The most common presentation was encephalitis (4) followed by pneumonia (1) and disseminated disease (1) . The brain is well described as the main site for toxoplasmosis disease and most cases have been reported as encephalitis [5, 13, 14] .
We observed that all cases occurred up to 6 months post-HSCT, which is in accordance with the literature and coincide with the period of most intense immunosuppression [1] . Although less common, 4 patients (A, B, C and F) had an unexpected early disease presentation, what is a relatively rare finding according to previous studies [3, 7] . Interestingly, three of the four early cases received myeloablative conditioning regimen. This relationship of the conditioning regimen type and the risk for early toxoplasmosis reactivation post-HSCT has been previously reported and suggests that early toxoplasmosis-risk strategy might be consider for high-risk HSCT [12] .
The majority of patients had fever (n = 4), and the main symptoms presented were altered mental status alone (n = 2); fever associated with altered mental status (n = 2), fever with respiratory distress (n = 1) and fever with skin lesions (n = 1). The onset of symptoms had a median of 17 days after HSCT (range, 2-150 days) and the median time from HSCT to diagnosis was 23 days (range, 17-163). Curiously, the median time from symptoms onset and diagnosis was AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic myeloid leukemia, GVHD graft-versus-host disease, HSCT hematopoietic stem cell transplant, SMZ/TMP trimethoprin-sulphametoxazole, PCR polymerase chain reaction, SDZ/PYR sulphadiazine with pirimethamine 13 days (range, 3-16). It illustrates the diagnostic challenges of the disease in the HSCT population. Most cases of toxoplasmosis disease occur in allo-HSCT patients, although a small number of autologous has been identified [3, 4] . The majority of our patients underwent allo-HSCT (80%); however, one patient (patient B) was an auto-HSCT who developed a fatal disseminated disease with a pulmonary involvement. Although the incidence of toxoplasmosis in this population has been reported as very low, this observation highlights the importance of include toxoplasmosis as a differential diagnosis even in auto-HSCT seropositive patients.
Five patients were receiving PJP prophylaxis at the onset of toxoplasmosis although in different daily doses [(median 80 mg per day, range 80-320 mg per day of TMP)]. Whereas toxoplasmosis disease is considered rare in patients on SMZ-TMP prophylaxis, cases have been reported despite prophylaxis use [11, 14] . Martino et al. prospectively analyzed 106 allo-HSCT patients and described an incidence of infection and disease of 16 and 9% respectively. The authors reported 14% of inadequate compliance to SMZ-TMP prophylaxis and identified this predictor as a risk factor for both T. gondii infection and disease [7] .
Acute GVHD was identified in four cases and the maximum grade was II. Five patients were receiving steroids at the time of diagnosis. All cases had a normal neutrophil count at the time of disease presentation, however, five were lymphopenic (absolute lymphocyte count <500 cells/μL).
We observed an overall mortality of 50%. Curiously, 2 (patients A and F) of those 3 who died, were diagnosed after death and one (patient B), who had a positive PCR on blood, died just after the treatment onset. Likewise, the two patients diagnosed post-mortem had a delay in the diagnosis (15 and 14 days from symptoms onset to diagnosis, respectively). Of the three patients who got treatment, two have received sulphadiazine with pirimethamine and one patient was treated with TMP/SMZ.
These findings reinforce the requirement of a diagnosis strategy for high-risk HSCT patients, given the highly variability of clinical presentation and low index of suspicion of the disease. In this context, the significance of a molecular detection of Toxoplasma by PCR has been extensively debated [6] . Authors suggested a preemptive weekly approach using PCR on peripheral blood samples for high-risk HSCT recipients [1, 2, 7] . These authors described detectable parasitaemia before the onset of clinical toxoplasmosis and showed a reduction of disease progression in patients who underwent preemptive therapy [1, 2, 7] . However, the lack of a standardized PCR assay and the common use of the so-called "in-house" tests are the main issues that have been discussed regarding the introduction of routine molecular methods for early diagnosis [6] .
Thus, our findings highlight the importance of a clinical awareness to suspect of toxoplasmosis in high-risk HSCT patients from endemic areas and reinforce the need for development of a standardized PCR for preemptive protocols as well as early prophylaxis for those patients.
